Advances in targeted breast cancer therapy

Current Breast Cancer Reports

Volumn 2, Issue 3, 2010, Pages 146-151

  Elhazzat, Jallal ^a   El Sayed, Mohamed E H ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Breast cancer; Chemotherapy; Dendrimers; Liposomes; Micelles; Nucleic acids

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; CYTARABINE; DENDRIMER; DOXORUBICIN; DRUG CARRIER; GEMCITABINE; LIPOSOME; METHOTREXATE; NAVELBINE; NUCLEIC ACID; PEPTIDE DERIVATIVE; PLASMID DNA; POLYMER; SMALL INTERFERING RNA;

BIOCOMPATIBILITY; BREAST CANCER; CANCER CELL; CYTOPLASM; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG SOLUBILITY; DRUG TARGETING; ENDOCYTOSIS; GENE DELIVERY SYSTEM; HUMAN; MICELLE; NONHUMAN; REVIEW;

EID: 77955549496     PISSN: 19434588     EISSN: 19434596     Source Type: Journal    
DOI: 10.1007/s12609-010-0019-z     Document Type: Review

References (71)

1. A Jemal R Siegel E Ward, et al. 2009 Cancer statistics Cancer J Clin 59 225 249 10.3322/caac.20006
2. Takimoto CH, Calvo E: Principles of oncologic pharmacotherapy. In Cancer Management: A Multidisciplinary Approach, edn 11. Edited by Pazdur R, Wagman LD, Camphausen K. London: Cmp United Business Media; 2008:Chapter 3, 1-9.
3. Y Luo G Prestwich 2002 Cancer-targeted polymeric drugs Curr Cancer Drug Targets 2 209 226 10.2174/1568009023333836 12188908
4. E Igarashi 2008 Factors affecting toxicity and efficacy of polymeric nanomedicines Toxicol Appl Pharmacol 229 121 134 10.1016/j.taap.2008.02.007 18355886
5. A Mahmud X Xiong H Aliabadi A Lavasanifar 2007 Polymeric micelles for drug targeting J Drug Target 15 553 584 10.1080/10611860701538586 17968711 (Pubitemid 350031081)
6. VP Torchilin 2004 Targeted polymeric micelles for delivery of poorly soluble drugs Cell Mol Life Sci 61 2549 2559 10.1007/s00018-004-4153-5 15526161 (Pubitemid 39591627)
7. S Svenson D Tomalia 2005 Dendrimers in biomedical applications- reflections on the field Adv Drug Deliv Rev 57 2106 2129 10.1016/j.addr.2005.09. 018 16305813 (Pubitemid 41759389)
8. H Maeda T Sawa T Konno 2001 Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS J Control Release 74 47 61 10.1016/S0168-3659(01)00309-1 11489482 (Pubitemid 32727608)
9. F Yuan M Dellian D Fukumura, et al. 1995 Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size Cancer Res 55 3752 3756 7641188
10. A Bangham 1961 A correlation between surface charge and coagulant action of phospholipids Nature 192 1197 1198 10.1038/1921197a0 13864660
11. Y Ning K He R Dagher, et al. 2007 Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma Oncology (Williston Park) 21 1503 1508
12. M Mozafari 2005 Liposomes: an overview of manufacturing techniques Cell Mol Biol Lett 10 711 719 16341279
13. S Vemuri C Rhodes 1995 Preparation and characterization of liposomes as therapeutic delivery systems Pharm Acta Helv 70 95 111 10.1016/0031-6865(95) 00010-7 7651973
14. W Bawarski E Chidlowsky D Bharali S Mousa 2008 Emerging nanopharmaceuticals Nanomedicine 4 2732 2782
15. L Qiu N Jing Y Jin 2008 Preparation and in vitro evaluation of liposomal chloroquine diphosphate loaded by a transmembrane pH-gradient method Int J Pharm 361 56 63 10.1016/j.ijpharm.2008.05.010 18573626
16. Y Malam M Loizidou A Seifalian 2009 Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer Trends Pharmacol Sci 30 592 599 10.1016/j.tips.2009.08.004 19837467
17. R Hofheinz S Gnad-Vogt U Beyer A Hochhaus 2005 Liposomal encapsulated anti-cancer drugs Anticancer Drugs 16 691 707 10.1097/01.cad.0000167902.53039.5a 16027517 (Pubitemid 41104918)
18. M Markman 2006 Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary Expert Opin Pharmacother 7 1469 1474 10.1517/14656566.7.11.1469 16859430 (Pubitemid 44173208)
19. D Papahadjopoulos T Allen A Gabizon, et al. 1991 Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy Proc Natl Acad Sci 88 11460 11464 10.1073/pnas.88.24.11460 1763060
20. A Klibanov A Klibanov K Maruyama, et al. 1990 Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes FEBS Lett 268 235 237 10.1016/0014-5793(90)81016-H 2384160 (Pubitemid 20233874)
21. J Senior C Delgado D Booser, et al. 1991 Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles Biochim Biophys Acta 1062 77 82 10.1016/0005-2736(91)90337-8 1998713
22. M Woodle 1993 Surface-modified liposomes: assessment and characterization for increased stability and prolonged blood circulation Chem Phys Lipids 64 249 262 10.1016/0009-3084(93)90069-F 8242837
23. J Senior 1987 Fate and behavior of liposomes in vivo: a review of controlling factors Crit Rev Ther Drug Carrier Syst 3 123 193 3542245
24. V Torchilin 1996 Affinity liposomes in vivo: factors influencing target accumulation J Mol Recognit 9 335 346 10.1002/(SICI)1099-1352(199634/12)9:5/ 6<335::AID-JMR309>3.0.CO;2-0 9174907
25. K Ogawara K Un K Tanaka, et al. 2009 In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: involvement of cytotoxic effect on vascular endothelial cells J Control Release 133 4 10 10.1016/j.jconrel.2008.09.008 18840484
26. K Ogawara K Un K Minato, et al. 2008 Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors Int J Pharm 359 234 240 10.1016/j.ijpharm.2008.03.025 18448289
27. O Lyass B Uziely R Ben-Yosef, et al. 2000 Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma Cancer J Clin 89 1037 1047
28. H Burstein M Ramirez W Petros, et al. 1999 Phase I study of Doxil and vinorelbine in metastatic breast cancer Ann Oncol 10 1113 1116 10.1023/A:1008323200102 10572612 (Pubitemid 29482469)
29. E Rivera V Valero L Syrewicz, et al. 2001 Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer J Clin Oncol 19 1716 1722 11251001 (Pubitemid 32230872)
30. E Buhleier W Wehner F Vogtle 1978 Cascade and nonskid-chain-like synthesis of molecular cavity topologies Synthesis 55 155 158 10.1055/s-1978-24702
31. D Tomalia H Baker JR Dewald, et al. 1985 A new class of polymers: starburst-dendritic macromolecules Polym J 17 117 132 10.1295/polymj.17.117
32. C Dufès I Uchegbu A Schätzlein 2005 Dendrimers in gene delivery Adv Drug Deliv Rev 57 2177 2202 10.1016/j.addr.2005.09.017 16310284 (Pubitemid 41759392)
33. A Bosman H Janssen E Meijer 1999 About dendrimers: structure, physical properties, and applications Chem Rev 99 1665 1688 10.1021/cr970069y 11849007
34. D Tomalia L Reyna S Svenson 2007 Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging Biochem Soc Trans 35 61 67 10.1042/BST0350061 17233602
35. E Gillies J Fréchet 2005 Dendrimers and dendritic polymers in drug delivery Drug Discov Today 10 35 43 10.1016/S1359-6446(04)03276-3 15676297 (Pubitemid 40164817)
36. R Duncan 1992 Drug-polymer conjugates: potential for improved chemotherapy Anticancer Drugs 3 175 210 10.1097/00001813-199206000-00001 1525399
37. CE Kojima K Kono K Maruyama T Takagishi 2000 Synthesis of polyamidoamine dendrimers havingpoly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs Bioconjug Chem 11 910 917 10.1021/bc0000583 11087341
38. J Haensler F Szoka 1993 Polyamidoamine cascade polymers mediate efficient transfection of cells in culture Bioconjug Chem 4 372 379 10.1021/bc00023a012 8274523
39. JF Jansen EM de Brabander-van den Berg EW Meijer 1994 Encapsulation of guest molecules into a dendritic box Science 266 1226 1229 10.1126/science.266. 5188.1226 17810265
40. CJ Hawker KL Wooleyb JMJ Frechet 1993 Unimolecular micelles and globular amphiphiles: dendritic macromolecules as novel recyclable solubilization agents J Chem Soc Perkin Trans 1 1287 1297 10.1039/p19930001287
41. D Bhadra S Bhadra S Jain NK Jain 2003 A PEGylated dendritic nanoparticle carrier of fluorouracil Int J Pharm 257 1-2 111 124 10.1016/S0378-5173(03)00132- 7 12711167 (Pubitemid 36507038)
42. N Malik EG Evagorou R Duncan 1999 Dendrimer-platinate: a novel approach to cancer chemotherapy Anticancer Drugs 10 767 776 10.1097/00001813-199909000- 00010 10573209
43. R Duncan N Malik 1996 Dendrimers: biocompatibility and potential for delivery of anticancer agents Proc Int Symp Control Release Bioact Matter 23 105 106
44. YH Choe CD Conover D Wu, et al. 2002 Anticancer drug delivery systems: multi-loaded N4-acyl poly(ethylene glycol) prodrugs of ara-C. II. Efficacy in ascites and solid tumors J. Control. Release 79 55 70 10.1016/S0168-3659(01) 00470-9 11853918 (Pubitemid 34164161)
45. O Schiavon G Pasut S Moro, et al. 2004 PEG-Ara-C conjugates for controlled release Eur J Med Chem 39 123 133 10.1016/j.ejmech.2003.10.005 14987821 (Pubitemid 38249525)
46. K Kono M Liu JM Fréchet, et al. 1999 Design of dendritic macromolecules containing folate or methotrexate residues Bioconjug Chem 10 1115 1121 10.1021/bc990082k 10563782
47. J Sudimack RJ Lee 2000 Targeted drug delivery via the folate receptor Adv Drug Deliv 41 147 162 10.1016/S0169-409X(99)00062-9 (Pubitemid 30122955)
48. A Quintana E Raczka L Piehler, et al. 2002 Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor Pharm Res 19 1310 1316 10.1023/A:1020398624602 12403067
49. G Kwon T Okano 1999 Soluble self-assembled block copolymers for drug delivery Pharm Res 16 597 600 10.1023/A:1011991617857 10349998 (Pubitemid 29227085)
50. Torchilin V, and Trubetskoy V.: Biodistribution of surface-modified liposomes and particles In Microparticulate. Systems for the Delivery of Proteins and Vaccines. Edited by Cohen S, Bernstein H: Boca Raton, FL: CRC Press; 1996:243-277.
51. T Inoue G Chen K Nakamae A Hoffman, et al. 1998 An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs J Control Release 51 221 229 10.1016/S0168-3659(97)00172-7 9685920 (Pubitemid 28252874)
52. R Kuntz W Saltzman 1997 Polymeric controlled delivery for immunization Trends Biotechnol 15 364 369 10.1016/S0167-7799(97)01087-1 9293035 (Pubitemid 27368499)
53. K Cho X Wang S Nie, et al. 2008 Therapeutic nanoparticles for drug delivery in cancer Clin Cancer Res 14 1310 1316 10.1158/1078-0432.CCR-07-1441 18316549 (Pubitemid 351413909)
54. G Kwon M Naito M Yokoyama, et al. 1995 Physical entrapment of adriamycin in AB block copolymer micelles Pharm Res 12 192 195 10.1023/A:1016266523505 7784332
55. E Batrakova TY Dorodnych EY Klinskii, et al. 1996 Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity Br J Cancer 74 1545 1552 8932333
56. T Nakanishi S Fukushima K Okamoto, et al. 2001 Development of the polymer micelle carrier system for doxorubicin J Control Release 74 295 302 10.1016/S0168-3659(01)00341-8 11489509 (Pubitemid 32727635)
57. Y Nagasaki K Yasugi Y Yamamoto, et al. 2001 Sugar-installed block copolymer micelles: their preparation and specific interaction with lectin molecules Biomacromolecules 2 1067 1070 10.1021/bm015574q 11777374 (Pubitemid 34026879)
58. S Vinogradov E Batrakova S Li A Kabanov 1999 Polyion complex micelles with protein-modified corona for receptor-mediated delivery of oligonucleotides into cells Bioconjugate Chem 10 851 860 10.1021/bc990037c (Pubitemid 29456374)
59. C Leamon D Weigl R Hendren 1999 Folate copolymer-mediated transfection of cultured cells Bioconjugate Chem 10 947 957 10.1021/bc990066n
60. E Lee K Na Y Bae 2003 Polymeric micelle for tumor pH and folate-mediated targeting J Control Release 91 103 113 10.1016/S0168-3659(03)00239-6 12932642 (Pubitemid 37288881)
61. Z Gao D Lee D Kim Y Bae 2005 Doxorubicin loaded pH-sensitive micelle targeting acidic extracellular pH of human ovarian A2780 tumor in mice J Drug Target 13 391 397 10.1080/10611860500376741 16308207 (Pubitemid 43084539)
62. B Urban-Klein S Werth S Abuharbeid, et al. 2005 RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo Gene Ther 12 461 466 10.1038/sj.gt.3302425 15616603 (Pubitemid 40394299)
63. A Choudhury J Charo SK Parapuram, et al. 2004 Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines Int J Cancer 108 71 77 10.1002/ijc.11497 14618618 (Pubitemid 37444446)
64. K Whitehead R Langer D Anderson 2009 Knocking down barriers: advances in siRNA delivery Nat Rev Drug Discov 8 129 138 10.1038/nrd2742 19180106
65. F Takeshita T Ochiya 2006 Therapeutic potential of RNA interference against cancer Cancer Sci 97 689 696 10.1111/j.1349-7006.2006.00234.x 16863503 (Pubitemid 43983779)
66. GL Storvold TI Andersen CM Perou, et al. 2006 siRNA a potential tool for future breast cancer therapy Crit Rev Oncogenesis 12 127 150 17078209
67. A Akinc M Thomas A Klibanov R Langer, et al. 2005 Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis J Gene Med 7 657 663 10.1002/jgm.696 15543529 (Pubitemid 40744532)
68. N Sonawane FC Szoka Jr AS Verkman, et al. 2003 Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes J Biol Chem 278 44826 44831 10.1074/jbc.M308643200 12944394 (Pubitemid 37377241)
69. YW Cho J Kim K Park 2003 Polycation gene delivery systems: escape from endosomes to cytosol J Pharm Pharmacol 55 721 734 10.1211/002235703765951311 12841931 (Pubitemid 36752715)
70. K Berg P Selbo L Prasmickaite, et al. 1999 Photochemical internalization: a novel technology or delivery of macromolecules into cytosol Cancer Res 59 1180 1183 10096543
71. J Menendez L Vellon R Colomer R Lupu 2005 Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity Int J Cancer 115 19 35 10.1002/ijc.20754 15657900 (Pubitemid 40559665)